CTLA4 and melanoma: In two independent cohorts of 105 and 38 melanoma patients treated with ipilimumab (anti-CTLA4) and pembrolizumab (anti-PD1), respectively, we find that B2M LOH is enriched threefold in non-responders (~30%) vs. responders (~10%) and associated with poorer overall survival (log-rank p = 0.01, p = 0.006).